Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements (Level 3 Reconciliation) (Details)

v2.4.0.8
Fair Value Measurements (Level 3 Reconciliation) (Details) (USD $)
In Thousands, unless otherwise specified
9 Months Ended
Sep. 30, 2014
Assets:  
Fair value of level 3 financial instrument assets $ 11,746
Assumed payments made by Pfizer or assignee (1,002)
Fair value adjustments to co-promote termination liability (10,221)
Fair value of level 3 financial instrument assets 523
Liabilities:  
Fair value of level 3 financial instrument liabilities 21,057
Assumed payments made by Pfizer or assignee (1,002)
Payments to CVR and other former license holders (1,936)
Fair value adjustments to contingent liabilities 5,564
Fair value adjustments to co-promote termination liability (10,221)
Fair value of level 3 financial instrument liabilities $ 13,462